Concept of Mahagad in Ayurveda w.s.r. to Bhagandara (Fistula-In-Ano)

In Samhitas many concepts are explained as Leshokta (incompletely explained) or they have Linartha i.e. concept is not elaborated or proper meaning is difficult to understand. So there is a need to explore such concept to understand the vision of Ayurveda. The term ‘Mahagada’ is used as ‘Visheshana (attribute)’ for few diseases in various Ayurvedic Samhitas. Original Samhitas shows very little information regarding the term ‘Mahagada’. The concept of ‘Mahagada’ is useful to decide prognosis of diseases. Mahagada is a group of diseases having incurability, primarily due to development of complications. The conceptual study shows belief of ancient Ayurvedic Acharyas regarding concept of Mahagada and clinical survey was done to support the concept. On the basis of collected data, efforts were made to throw light on the concept of Mahagada

Fundamental approach in the management of Drava Bahula Amlapitta with Bhringaraja (Eclipta alba)

The disease Amlapitta has been selected for the clinical trials because it presents two type of manifestations depending upon the involvement of Agni (Ushnagunadhikya) and Jala (Dravagunadhikya) Mahabhuta. The present research work was focused at Drava Guna, with an aim to assess the efficacy of a drug with quality of Ruksha and Ushna predominance like Bhringaraja in treating Amlapitta with Pitta Drava Guna Vriddhi. Randomized open clinical trials were conducted on 22 patients of Amlapitta who were screened on the basis of clinical findings and allocated in to two groups. The criteria for selection were the signs and symptoms of Dravagunadhikya Amlapitta, irrespective of sex, religion, etc. Group A consisting of 15 cases received the trial drug Bhringaraja tablet (4 Tab. two times, 1 tablet=500 mg) and 7 cases in Group B received rice powder tablet as a placebo (4 Tab. two times, 1 tablet=500 mg) for 4 weeks. Special scoring pattern was adopted for the assessment of Amlapitta. Routine pathological tests such as blood, urine, stool, etc. were also carried out. In Group A, 55.33% patients showed marked improvement, whereas moderate improvement was observed in 26.67% patients. Complete cure was found in 06.67% of the patients and mild improvement in the chief complaints was observed in 13.33% patients. All the selected symptoms showed statistically significant results (P<0.01) except the Vidbheda in treated Group A, while in Group B, all symptoms showed statistically insignificant results except the Utklesha and Amlodgara. Total effect of the therapy showed statistically significant effect of the test drug. These results support the hypothesi